Highlights

  • BlinkLab reported ADHD diagnostic study results showing 82% sensitivity and 83% specificity.
  • The company is progressing its autism diagnostic program toward a potential FDA submission by the end of 2026.
  • BlinkLab reported approximately A$17.9 million in Liquidity at 30 June 2026.
  • The company is developing smartphone-based artificial intelligence diagnostics for neurodevelopmental conditions.

BlinkLab (ASX:BB1) is developing smartphone-based diagnostic technology designed to identify neurodevelopmental conditions including autism and attention Deficit hyperactivity disorder (ADHD). The digital health company uses artificial intelligence software to analyse subtle facial and eye movements captured through smartphone cameras.

At the time of writing on 14 August 2026, BlinkLab (ASX:BB1) was trading at AUD 0.67, down 0.37% on the day.

The company is progressing its autism diagnostic program toward a potential United States regulatory submission while expanding its pipeline through early ADHD diagnostic research.

What Just Happened?

On 5 August 2026, BlinkLab reported results from a study evaluating its second diagnostic product, Dx2, which targets ADHD-related neurobehavioural traits.

The company reported that the smartphone-based test achieved 82% sensitivity and 83% specificity in detecting ADHD-related traits. The study involved 208 Dutch children aged between six and 17, including 117 participants with a clinical ADHD diagnosis and 91 participants in a comparison group.

BlinkLab stated that it intends to pursue a similar regulatory pathway for Dx2 as its autism diagnostic product. However, the ADHD results are based on a single observational study and have not yet been peer-reviewed, independently validated or replicated through a formal regulatory trial.

The company is also progressing its autism diagnostic program, with a pivotal United States validation study underway to support a potential regulatory submission by the end of 2026.

Why It Matters

BlinkLab’s technology aims to address challenges in diagnosing autism and ADHD, where assessments can involve specialist input, extended waiting periods and complex evaluation processes.

A smartphone-based diagnostic tool could potentially provide a more accessible screening approach by using existing consumer devices and artificial intelligence-based analysis.

The ADHD data expands BlinkLab’s potential market beyond autism, creating an additional development pathway for the company’s technology platform.

Financial resources remain important as the company progresses clinical and regulatory activities. In April 2026, BlinkLab raised A$17.5 million through a placement, while at 30 June 2026 it reported approximately A$17.9 million in liquidity, including A$7.9 million in cash and A$10 million in short-term investments.

The Bigger Picture

BlinkLab’s technology uses smartphone cameras to capture subtle reflexive movements and responses, with machine-learning models analysing patterns associated with neurodevelopmental conditions.

The company’s lead product, Dx1, is focused on autism diagnosis, while Dx2 is being developed for ADHD applications. Both products are designed to operate without specialist equipment, supporting the company’s focus on accessibility.

The autism program remains the more advanced development pathway. BlinkLab has been conducting a pivotal validation program across 10 United States clinical sites, with support from contract research partner IQVIA-MCRA.

The company reported that an earlier pilot study in October 2025 showed 83.7% sensitivity and 84.7% specificity. BlinkLab is targeting a potential submission to the United States Food and Drug Administration through the 510(k) pathway by the end of 2026.

What Could Drive the Shares Next?

The key milestone for BlinkLab remains progress in the autism diagnostic program. Completion of enrolment, reporting of pivotal trial results and submission of a regulatory package to the United States Food and Drug Administration are the main developments to monitor.

Further ADHD development may also influence expectations, particularly if the company progresses toward peer-reviewed research, independent validation or formal regulatory studies.

Additional factors including commercial partnerships, healthcare adoption pathways and reimbursement developments may provide further insight into the potential commercial pathway for BlinkLab’s technology.

Risks Investors Should Watch

BlinkLab faces clinical, regulatory, funding and commercialisation risks associated with developing medical technology. FDA submission does not guarantee regulatory clearance, and clinical trial outcomes may differ from earlier studies. The company remains pre-revenue and may require additional Capital to fund ongoing development, creating potential dilution risks. Commercial adoption depends on acceptance by clinicians, healthcare providers and reimbursement systems. The ADHD results remain early-stage and require further validation. Additional risks include competition in digital diagnostics and Volatility associated with smaller ASX-listed biotechnology and healthcare companies.

Bottom Line

BlinkLab (ASX:BB1) is progressing a smartphone-based diagnostic platform targeting autism and ADHD, with its autism program moving toward a potential FDA submission and new ADHD data expanding the technology’s application.

The company has reported early diagnostic performance indicators, alongside a Balance Sheet supporting continued development activities. However, the Business remains at a pre-commercial stage, with future value dependent on regulatory outcomes, clinical validation and successful commercialisation.

The upcoming autism trial milestones and further validation of the ADHD program will remain key areas for investors to monitor.